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Abstract
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor expressed in many cell types, including
osteoblasts, osteocytes, and osteoclasts. Nrf2 has been considered a master regulator of cytoprotective genes
against oxidative and chemical insults. The lack of Nrf2 can induce pathologies in multiple organs. Nrf2 deficiency
promotes osteoclast differentiation and osteoclast activity, which leads to an increase in bone resorption. The role
of Nrf2 in osteoblast differentiation and osteoblast activity is more complex. Nrf2 mediates anabolic effects within
an ideal range. Nrf2 deletion suppresses load induced bone formation and delays fracture healing. Overall, Nrf2
plays an important role in the regulation of bone homeostasis in bone cells.
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Review
Mammalian bone tissue has a distinct composition and
functions that set it apart from most other organs. There
are a number of important functions carried out by
bone. The skeleton’s primary function is to provide
movement and support for the body that will withstand
the daily challenges of weight bearing, to protect internal
organs, and to maintain posture. Bones also act as a
mineral reservoir, a growth factor and a fat repository.
Ninety percent of calcium and 85 % of phosphate min-
erals are stored in bones [1]. Calcium and phosphate can
be mobilized to sustain mineral homeostasis. Some of
the most important regulators in skeletal metabolism in-
clude parathyroid hormone, calcitonin, Vitamin D, para-
thyroid hormone-related protein, insulin-like growth
factor-1, and bone morphogenetic proteins [2–4].
Bone metabolism is a complex process that occurs
throughout a lifetime. Bones are constantly changed
through two processes: modeling and remodeling [5–7].
Bone modeling is the process of the formation of new
bone that changes the shape of bones to adjust to forces
in the environment. Bone remodeling is the process of
the removal of old bone tissue that is being replaced
with new tissue, which is essential for bone mineral
homeostasis. Osteoblasts and osteocytes play two im-
portant roles in these two processes [8]. Osteoblasts
secret bone matrix and control the mineralization of the
bone. On the cell surface of osteoblasts are receptors for
hormones such as vitamin D, estrogen, parathyroid
hormone and parathyroid hormone-related protein.
Osteocytes are thought to direct bone modeling and re-
modeling to accommodate mechanical strain and to re-
pair damage [9]. They also activate osteoblasts to secrete
RANK (Receptor Activator of Nuclear Factor κ B) - lig-
and that stimulates osteoclast differentiation. Osteoclasts
and osteoblasts work together to remove old bone and
add new bone [10]. Osteoclasts are activated by RANK-
ligand to resorb old bone and release growth factors,
such as TGF-beta, and to activate the migration of oste-
oblasts, which then deposit new bone matrix and or-
chestrate the mineralizing process.
Decreased levels of bone remodeling, or an imbalance
between bone resorption and bone formation, have been
linked to age-related bone loss, such as osteoporosis
[11]. Osteoporosis is characterized by low bone mass
and structural deterioration of bone tissue, leading to
bone fragility and an increased susceptibility to fractures,
especially of the hip, spine, and wrist. Osteoporosis oc-
curs primarily as a result of normal aging, but can arise
as a result of impaired development of peak bone mass
or excessive bone loss during adulthood. Bone density
scanners can measure bone mineral density and detect
the disease. A report by the World Health Organization
shows that fracture rates increase rapidly with age and
the lifetime risk of fracture in 50 year-old women is
about 40 % [12]. In 1990, there were 1.7 million hip
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fractures alone worldwide; with changes in population
demographics, this figure is expected to rise to 6 million
by 2050. The underlying molecular pathways leading to
osteoporosis have not been well understood. In order to
effectively select targets for therapeutic intervention of
skeletal defects, it is essential to elucidate the basic mo-
lecular interaction in bone formation and resorption.
The following review will focus on how the transcrip-
tion factor Nrf2 and its signaling cascade mediate differ-
entiation, growth, and maintenance of osteoprogenitor
cells and osteoclast precursors as well as their terminally
differentiated lineage constituents. Also discussed are
pathologies that arise when this pathway becomes
disrupted.
Overall roles of Nrf2
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a
transcription factor expressed in many cell types, includ-
ing osteoblasts, osteocytes, and osteoclasts. Nrf2 has been
considered a master regulator of cytoprotective genes
against oxidative and chemical insults. It belongs to a
basic leucine zipper protein family [13], which comprises
four members, namely Nrf1, Nrf2, Nrf3 and p45 NF-E2.
Nrf1 and Nrf2 are ubiquitously expressed, whereas the ex-
pression of Nrf3 is restricted to placenta and liver, and
NF-E2 is restricted to erythrocytes. Among these four
members, Nrf2 is the main mediator of cellular adaptation
to redox stress. The various domains of Nrf2 are shown in
Fig. 1 [14]. It contains an N-terminal hydrophobic do-
main, Keap1-binding domain, transcriptional activation
domain, CNC domain, and basic and leucine zipper do-
mains. Nrf2 through its leucine zipper domain, heterodi-
merizes with small Maf or Jun proteins and binds to an
antioxidant response element (ARE). Keap1 (Kelch-like
ECH-associated protein 1), a homodimeric protein, retains
Nrf2 for Cul3/Rbx1-mediated degradation of Nrf2.
Nrf2 is a key regulator of constitutive and inducible
gene expression of phase II detoxifying enzymes and
antioxidant proteins and is mainly expressed in meta-
bolic and detoxification organs, such as the liver and
kidney, as well as in organs that are continuously ex-
posed to the environment, such as the skin, lungs, and
digestive tract [15]. The molecular mechanisms of Nrf2
activation and transactivation activity have been revealed
in recent years. As shown in Fig. 2, Keap1, a cytoplasmic
actin-binding protein, tethers Nrf2 in the cytoplasm and
represses the transactivation activity of Nrf2 under nor-
mal quiescent conditions [16]. Keap1 functions as a sen-
sor protein of xenobiotics and oxidative stress. After
exposure to either inducers of detoxifying enzymes or
reactive metabolic intermediates produced by phase I
bioactivation, Keap1 is modified, leading to the release
of Nrf2 from Keap1, with the subsequent translocation
of Nrf2 into the nucleus. Activated Nrf2 forms heterodi-
mers with cofactors such as Small Maf proteins (sMafK
and sMafG), and binds to an antioxidant response elem-
ent (ARE), which exists in the regulatory regions of
genes encoding detoxifying enzymes and antioxidant
proteins, such as glutathione S-transferases (GSTs),
NAD(P)H:quinone oxidoreductase (NQO) 1, and
glutamate-cysteine ligase catalytic (GCLC) subunit
[17–19], and transactivates the expression of these
genes in many tissues, including bone and cartilage
[20–22]. The ARE core sequence follows a pattern of
TGACnnnGC [23]. Nrf2-ARE pathways are now recog-
nized as one of the major cellular defense mechanisms
against oxidative and xenobiotic stresses, and contrib-
ute to protection from various pathologies, including
carcinogenesis, liver toxicity, respiratory distress, and
inflammation [15]. Hence, Nrf2 has been considered as
a novel molecular target for chemoprevention [21]. The
importance of Nrf2 in many cytoprotective activities has
Fig. 1 Structural domains of Nrf2 and Keap1. Nrf2 contains an N-terminal hydrophobic domain, followed by a Keap1-binding domain,
transcriptional activation domain, CNC domain, and basic and leucine zipper domains. Nrf2, through its leucine zipper domain, heterodimerizes with
small Maf or Jun proteins and binds to the ARE. Keap1, a homodimeric protein, retains Nrf2 in the cytoplasm. Keap1 functions as an adaptor for
Cul3/Rbx1-mediated degradation of Nrf2. Keap1 with its BTB domain binds to Rbx1-bound Cul3, and its double-glycine repeat/Kelch (DGR)
domain binds to Nrf2 and subsequently causes ubiquitination and degradation of Nrf2. BTB and DGR domains are separated by the intervening
region (IVR)
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been clearly illustrated through the use of Nrf2 knockout
(KO, Nrf2−/−) mice [24]. The Nrf2 KO mice are more sus-
ceptible to pro-oxidant stimuli such as hyperoxia and
many chemicals, suggesting that Nrf2 plays an important
role in protecting a variety of tissues (lung, liver, kidney,
central nervous system, etc.) from a wide array of toxic in-
sults (electrophiles, reactive oxygen species, carcinogens,
etc.).
Roles of Nrf2 in bone homeostasis
The Nrf2 signaling pathway is emerging as an important
factor in the regulation of bone metabolism. Oxidative
stress induced by reactive oxygen species (ROS) in-
creases with aging and/or estrogen deficiency in post-
menopausal women and can adversely affect bone
homeostasis and leads to skeletal fragility [25, 26]. In
addition, antioxidant defenses are significantly decreased
in postmenopausal osteoporotic women [27]. There is a
possibility that the decrease in antioxidant systems in
osteoporotic women is linked to the Nrf2 signaling path-
way. Nrf2 deficiency leads to an increase in the intracel-
lular ROS (Reactive Oxygen Species) level and a defect
in the production of numerous antioxidant enzymes and
glutathione in both osteoclast precursors and osteoblast
progenitor cells [28, 29]. A normal balance between oxi-
dants and antioxidants seems to be needed for the main-
tenance of a correct equilibrium between osteoblast and
osteoclast activities, respectively [30]. Increased osteo-
clastic activity and decreased osteoblastic activity have
been shown to be associated with an imbalance between
oxidant and antioxidant status plasma biomarkers in
postmenopausal osteoporosis [31]. Animal studies have
shown that the deletion of Nrf2 in bone tissue leads to a
lower bone mass as demonstrated by lower bone mineral
density [32–35]. Without Nrf2 in mice, the bone
strength of femurs and vertebral bodies was significantly
Fig. 2 Activation of Keap1 and Nrf2 and their regulation in osteoblasts and osteoclasts. Oxidative Stress caused by aging and/or estrogen
deficiency inhibits Keap1 and releases Nrf2 which subsequently migrates into the nucleus and activates antioxidant genes. Antioxidant proteins
and GSH synthetase, which have positive effects on osteoblasts, negatively affect osteoclasts directly as well as indirectly via osteoblasts
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lower in comparison to the wild type controls. Further-
more, load-driven bone formation was significantly
inhibited in Nrf2-deficient mice compared to the con-
trols. These data clearly show that Nrf2 plays an import-
ant role in bone homeostasis and mechanotransduction
and further suggest that understanding of Nrf2 signaling
in bone cells may provide new insights into the molecu-
lar mechanisms underlying bone homeostasis and dis-
covery of new strategies to treat osteoporosis.
The lower bone mass and bone strength caused by
Nrf2 deficiency result from an imbalance between bone
formation and resorption. Histomorphometric measure-
ment at the distal femurs shows that bone volume is sig-
nificantly lower in Nrf2 KO mice than those of the
controls [35]. Bone resorption surface was significantly
greater and bone formation rate was significantly lower
in Nrf2 KO mice than in the controls [35]. The decline
in bone mass in Nrf2-deficient mice could be explained
via bone remodeling, which includes sequential and co-
ordinated activity of osteoclasts and osteoblasts to re-
move and restore old bone tissues continuously. In
addition, a previous study using age- and sex-matched
Nrf2+/+ and Nrf2−/− mice show that a loss of functional
Nrf2 increases radiation-induced bone loss [29]. These
studies indicate that Nrf2 plays an important role in
bone homeostasis.
Roles of Nrf2 in osteoclasts
Nrf2 signaling is involved in regulation of osteoclast for-
mation and activity. Osteoclasts are multinucleated cells
derived from hematopoietic stem cells. The key inducer
of osteoclast differentiation is RANK ligand primarily
produced by osteoblasts. Exposure of RAW264.7 macro-
phages to RANK ligand lowers Nrf2/Keap1 ratio and
leads to a decrease in the expression of Nrf2 dependent
enzymes, which are in favor of ROS signaling. Overex-
pression of Nrf2 enhances RANK ligand induced eleva-
tion in the level of antioxidant enzymes and suppressed
osteoclast differentiation. Deletion of Nrf2 suppresses
antioxidant enzymes but elevates the intracellular ROS
level in osteoclasts, subsequently increasing osteoclast
number and stimulating osteoclast activity [28, 36]. This
is consistent with a report showing that higher ROS in-
duced more osteoclast differentiation [37]. Increased ac-
tivity of p38 MAP kinase and NFATc1 induction, but
not the NF-κB pathway, is responsible for the elevated
level of ROS in Nrf2−/− mice [28].
Consistent with previous studies [28, 29, 34, 36], our
own data have shown that Nrf2 knockout results in an
increase in osteoclast number in distal femurs and
osteoclast surface in lumbar vertebrae, suggesting an in-
crease in bone resorption in Nrf2−/− mice [35]. Cell cul-
ture data show an increase in RANKL (RANK ligand)
expression from Nrf2-deficient osteoblasts, which was
also observed under stressful conditions, such as radi-
ation [29]. These data suggest the increase in osteoclast
number results from the higher expression of RANKL
from Nrf2−/− osteoblasts. On the contrary, overexpres-
sion of Nrf2 directly, or indirectly via inhibition of
Keap1, decreases RANKL expression and reduces osteo-
clast number [36]. This represents an indirect effect of
Nrf2 on osteoclast formation and activity. Further, Nrf2
may directly affect osteoclast activity via interfering with
the actin ring. Mature osteoclasts have a sealing zone
that consists of a ring of filamentous actin that is re-
quired for bone resorption [10]. Nrf2 deficiency pro-
motes RANK ligand induced actin ring formation and
bone resorption [28]. These data suggest that Nrf2 is ne-
cessary to maintain a normal range of bone resorption.
The role of Nrf2 in bone resorption has been focused
on the osteoclast differentiation influenced by ROS and
RANKL. Nrf2 activity in osteoclast progenitor cells and
osteoclasts has not been well studied. Nrf2 regulates
NFATc1 (Nuclear Factor of Activated T-cells, cytoplas-
mic 1) [34]. NFATc1 is considered as a master transcrip-
tion factor in osteoclastogenesis [38]. We hypothesize
that Nrf2 directly regulates osteoclastogenesis and osteo-
clast activity through interaction with NFATc1. In order
to test this hypothesis, osteoclast- specific Nrf2 deficient
mouse models should be studied.
Roles of Nrf2 in osteoblasts
The role of Nrf2 in osteoblast differentiation and activity
is quite controversial and may depend on factors, such
as age, sex, genetic background, and physiological versus
pathological conditions. Nrf2 is required for normal
postnatal bone acquisition [33]. Our own data indicate
that the lower bone mass of Nrf2−/− mice in comparison
with wild type controls not only results from an in-
creased bone resorption but also from reduced bone for-
mation, as shown by lower MAR (Mineral Appositional
Rate) and decreased bone formation rate at distal femurs
and lumbar vertebrae [35]. Deteriorated biomechanical
properties of femurs and even lumbar vertebral bodies
where bone mass was still not significantly decreased in
Nrf2-deficient mice are also observed. These data are
supported by another report that Nrf2-deficient osteo-
blasts lose their ability to differentiate and mineralize [29].
However, another study by Park et al. shows a higher bone
density in Nrf2−/− mice compared with the wild type con-
trols [34]. In this study, 9-week-old Nrf2-deficient mice
were analyzed, although the sex of the animals used was
not described. There are possibilities that the sex and/or
age as well as the genetic backgrounds would cause the
discrepancy between the report by Park et al. and others.
The role of Nrf2 in osteoblast progenitor cells may be
associated with the level of intracellular ROS. ROS is
elevated in Nrf2-deficient stromal cells [29]. Oxidative
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stress caused by increased ROS has an inhibitory effect
on osteoblast differentiation [39, 40]. On the other hand,
low physiological amounts of reactive species may be ne-
cessary to promote osteogenesis. Bone morphogenetic
protein 2 (BMP2) promotes differentiation of osteoblast
progenitor cells to mature osteoblasts via ROS produc-
tion by NOX4 (NADPH oxidase 4) [41]. Moreover,
hydrogen peroxide is produced by differentiation osteo-
progenitor cells and is required for mineralization and
expression of osteogenic marker genes [42]. These data
suggest that the relationship between osteoblastogenesis
and Nrf2 or ROS is rather complex.
It seems that overexpression of Nrf2 causes deleterious
effects in osteoblasts because overexpressing Nrf2 in
MC3T3-E1 osteoblastic cells inhibits Runx2 [20, 34].
Runx2 is a master transcription factor regulating both
embryonic bone development and postnatal osteoblastic
function [43]. Endochondral and intramembranous bone
formation is almost completely suppressed in mice defi-
cient for Runx2, and chondrocyte maturation is arrested
before the stage of hypertrophy [44, 45]. Based on this
evidence, some believe that Nrf2 might inhibit osteo-
blastogenesis. As a matter of fact, many transcription
factors in bone have narrow optimal expression ranges.
For example, Runx2 must be maintained at optimal
levels, as both Runx2 insufficient mice and Runx2 over-
expressing animals are osteopenic [46, 47]. Perhaps the
same is true of Nrf2, especially given its interactions
with Runx2. Similar observations have been found in
other tissues. For instance, mice with overexpression of
Nrf2 by inactivation of the Keap1 gene died before
weaning due to the hyperkeratotic lesions in the esopha-
gus and stomach, which led to obstruction of the upper
digestive tract [48]. Constitutively active Nrf2 impairs
liver regeneration in mice due to delayed hepatocyte
proliferation and enhanced apoptosis of hepatocytes
after liver injury [49]. Constitutively active Nrf2 in kera-
tinocytes causes skin abnormalities, including hair loss
[50]. These studies suggest that Nrf2 generates beneficial
effects in cells only within an ideal range.
The important role of Nrf2 in bone formation cells
can also be demonstrated during fracture repair as well
as in response to mechanical loading. Nrf2 expression is
activated during fracture healing [51]. Bone healing and
recovery of mechanical strength are retarded in the Nrf2
KO mice compared to the WT mice [51]. These changes
may be caused by the reduction in vascular endothelial
growth factor (VEGF) during fracture repair in Nrf2 KO
mice. These data suggest that Nrf2 plays an essential
role in bone regeneration.
Roles of Nrf2 in mechanotransduction
Nrf2 signaling is involved in mechanotransduction. Nrf2
and NQO1 (NAD(P)H:quinone oxidoreductase 1)
expression in calvarial osteoblasts increases in response to
fluid shear stress [35]. In an axial ulnar loading study
using Nrf2 KO mice [35], mineralizing surface and min-
eral appositional rate following the loading are signifi-
cantly reduced in comparison to the controls, suggesting
that osteoblast recruitment and activity are suppressed in
response to mechanical loading. Deletion of Nrf2 signifi-
cantly decreased NQO1 expression in calvarial osteo-
blasts. NQO1 is under transcriptional regulation by the
Keap1/Nrf2 pathway, so upregulation of NQO1 mRNA or
protein has been used extensively as a biomarker for Nrf2
activation [52, 53]. Further, upregulation of NQO1 pro-
tects the cells from oxidative damage due to the ability of
NQO1 to reduce superoxide to hydrogen peroxide and
generate antioxidant forms of vitamin E and co-enzyme Q
[54, 55]. These data support observations that mechanical
loading increases the oxidative stress in osteoblast-like
cells [56] and that exercise can also lead to an increase in
antioxidants in bone [57]. It is not clear if exercise induces
oxidative stress and the antioxidant in parallel or if the
antioxidant is a response to oxidative stress during exer-
cise. It is reasonable to speculate that oxidative stress
would be overproduced if the antioxidant system were im-
paired during mechanical loading. The enhanced oxidative
stress may further disrupt the loading-induced bone for-
mation via antagonizing Wnt molecules such as Wnt5a
[35], a noncanonical Wnt ligand with anabolic effects on
bone formation [58]. These data suggest an essential role
of Nrf2 in mechanotransduction.
Conclusion
Nrf2 plays an important role in the regulation of bone
homeostasis in bone cells. The loss-of-function muta-
tions of Nrf2 reduce bone mass and load-driven anabolic
responses. So far the role of Nrf2 in bone homeostasis
has been investigated using global Nrf2 deficient mouse
models. However, it may be difficult to exclude the influ-
ence of other tissues, such as endocrine organs, on bone
tissues and cells. In order to investigate the specific role of
Nrf2 in different cell populations, studying osteoclast-,
osteoblast- and osteocyte-specific Nrf2-deficient mouse
models would give more insight into the important role of
Nrf2 in bone homeostasis, mechanical properties, and
load-driven bone formation.
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